Last reviewed · How we verify
NCT07167225
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
trial testing Effectiveness of different recruitment approaches in Cigarette Smoking-Related Carcinoma in 150 participants. Currently enrolling.
1 September 2028
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 3 April 2025 |
| Primary completion | 1 September 2028 |
| Estimated completion | 1 September 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Effectiveness of different recruitment approaches
- Choice of study completion locations
- Cannabis Engagement Assessment
- E-cigarette dependence Scale
Conditions studied
- Cigarette Smoking-Related Carcinoma — all drugs for Cigarette Smoking-Related Carcinoma →
- E-Cig Use — all drugs for E-Cig Use →
Sponsor
Roswell Park Cancer Institute
Who can join
Adults 18 to 25, any sex, with Cigarette Smoking-Related Carcinoma or E-Cig Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07167225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cigarette Smoking-Related Carcinoma
Currently open trials in the same condition.
- NCT06816459 — Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults · EARLY_PHASE1 · recruiting
- NCT07111234 — Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences · NA · recruiting
- NCT06145763 — A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial · NA · recruiting
- NCT06763536 — Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia · NA · recruiting
- NCT06213532 — CONNECTing to LungCare · NA · recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07167225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07167225.